Analyser av Surgical Science

Surgical Science Q3 2024: Sequential improvements continue - Redeye

Redeye updates its estimates following Surgical Science’s Q3 2024 report, which beat our expectations.

Surgical Science Q3 2024: Slight top-line beat, margins roughly in line - Redeye

Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations.

Surgical Science Q2 2024: Solid sequential recovery, decent outlook - Redeye

Redeye updates its estimates following Surgical Science’s Q2 2024 report, which featured a sequential recovery after the company’s weak Q1.

Redeye • 23 Aug 07:32

Surgical Science Q2 2024: Sales in line, soft profitability due to revenue mix - Redeye

Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequential recovery after the company’s weak...

Redeye • 22 Aug 08:34

Surgical Science Q1 2024: Soft streak continues - Redeye

Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably below our estimates due to weak Educati...

Redeye • 16 May 07:17

Surgical Science Q1 2024: Strength in Industry/OEM, anaemic Education Products sales - Redeye

Redeye provides its initial take on Surgical Science’s Q1 2024 report, which featured contrasting developments for the company’s two busines...

Redeye • 15 May 08:54

Surgical Science Sweden Q4 2023: Long-term high quality, short-term black box - Redeye

Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusually soft end to the year that we failed to...

Redeye • 22 Feb 08:39

Surgical Science Q4 2023: Soft Q4 numbers - Redeye

Redeye provides its initial take on Surgical Science’s Q4 2023 report, which broadly underperformed our expectations.

Redeye • 21 Feb 09:01

Surgical Science Q3 2023: Weak growth, margins continued expanding - Redeye

Redeye updates its estimates following Surgical Science’s Q3 2023 report, which featured considerably lower-than-expected sales.

Redeye • 10 Nov 2023 13:38

Surgical Science Q3 2023: Weak top-line figures, strong margins - Redeye

Redeye provides its initial take on Surgical Science’s Q3 2023 report, which came in broadly below our estimates.

Redeye • 09 Nov 2023 10:04

Surgical Science Q2 2023: Short-term challenges – unchanged long-term prospects - Redeye

Redeye updates its estimates following Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’.

Redeye • 25 Aug 2023 07:33

Surgical Science Q2 2023: Industry/OEM sales in line but softness in Educational Products - Redeye

Redeye provides its initial take on Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’.

Redeye • 24 Aug 2023 08:54

Surgical Science Q1 2023: Outperformers tend to keep outperforming - Redeye

Redeye updates its estimates following Surgical Science’s Q1 2023 report, which took our forecasts to the woodshed.

Redeye • 17 May 2023 07:14

Surgical Science Q1 2023: Strong across the board - Redeye

Redeye provides its initial take on Surgical Science’s Q1 2023 report, which exceeded our estimates in most regards.

Redeye • 16 May 2023 08:55

Surgical Science Q4 2022: The growth story continues - Redeye

Redeye updates its estimates following Surgical Science’s Q4 2022 report, which broadly aligned with our expectations.

Redeye • 23 Feb 2023 13:01

Surgical Science: Q4 2022, Sales growth in line, slightly softer margins than anticipated - Redeye

Redeye provides its initial take on Surgical Science’s Q4 2022 report, broadly aligning with our estimates.

Redeye • 22 Feb 2023 09:07

Surgical Science Q3 2022: Dissecting the company’s Q3 numbers - Redeye

Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured solid sales growth and profitability.

Redeye • 11 Nov 2022 07:38

Surgical Science Q3 2022: Strong Educational Products sales - Redeye

Redeye provides its initial take on Surgical Science’s Q3 2022 report, which came in above our estimates.

Redeye • 10 Nov 2022 08:40

Surgical Science Sweden: Setting High Ambitions and Delivering on Them - Redeye

Redeye provides an updated view of our investment thesis of Surgical Science following the company posting excellent Q2 numbers.

Redeye • 29 Aug 2022 07:42

Surgical Science Q2: Initial take - Redeye

Redeye provides its initial take on Surgical Science’s Q2 2022 report, which came in above our estimates.

Redeye • 25 Aug 2022 09:00

Surgical Science Sweden: Entering the Medical Simulation Matrix - Redeye

Redeye initiates coverage of Surgical Science, a serial acquirer sporting healthy organic growth prospects.

Redeye • 22 Jun 2022 07:49

Börskollen

För dig med koll på börsen